




FEBRUARY 2022

Does early treatment with highly effective DMT improve prognosis for people with MS?

This month we bring you the happy news that PCORI have now approved our application to extend the enrolment period for DELIVER-MS to allow us to complete the study. We are delighted to have this chance and ask all sites to do anything you can to ensure we complete enrolment by the end of 2022. Five sites (Cardiff, Cleveland, Las Vegas, Nottingham and UCL) have now reached their recruitment goal and we are >75% enrolled. **We urge all sites to try to enrol one participant per month** so we can reach our target.

TOTAL ENROLMENT




MONTHLY ENROLLMENT AS OF 8TH FEB

<p><u>2+ participants</u></p> <ul style="list-style-type: none"> ➤ Cleveland (6) ➤ Nottingham (6) ➤ Swansea (5) ➤ Las Vegas (2) ➤ Buffalo (2) ➤ VCU (2) ➤ Leeds (2) 	<p><u>1 participant</u></p> <ul style="list-style-type: none"> ➤ Ohio Health ➤ Colorado ➤ Virginia 	<p><u>0 participants</u></p> <p>Please try to help us with this last push</p> <p>PS yes I know I am on the naughty list too this month...</p>
---	--	--

NEWS AND UPDATES

- 🧠 Congratulations to Swansea, Buffalo, VCU, Leeds and Las Vegas for amazing recruitment this month. We are hugely grateful for all your hard work. Myla at VCU has a 100% randomisation record so far!
- 🧠 Welcome back to Leicester and their new PI Dr Maz Matar.
- 🧠 We are currently working on understanding the race breakdown of participation within the DELIVER-MS study, aiming to ensure we are generating data that is representative:



FINAL THOUGHTS: LET'S COMPLETE DELIVER-MS!

We remain optimistic that we can fully enrol in the coming months. Equipose seems more relevant than ever and you can help produce data that could guide our treatment algorithms for the coming years.